Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HW091077
- Development stage
- Phase 2
- Lead developer
- Humanwell Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HW091077 is an investigational small molecule drug developed by Wuhan Humanwell Innovative Drug R & D Center. It is currently in Phase 1 clinical trials, primarily being evaluated for the treatment of intractable chronic cough. The available studies focus on assessing its safety, tolerability, and pharmacokinetic characteristics after single and multiple ascending oral doses in healthy subjects. Additional objectives include evaluating the effect of food on its pharmacokinetics and exploring potential effects on cardiac QT/QTc intervals. As of now, detailed information about its precise mechanism of action or molecular target has not been disclosed[1][2][3][4].
Beyond the preview
Go deeper on HW091077.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HW091077.